[1]Sattar N, Forrest E, Preiss D. Non-alcohol fatty liver disease [J]. BMJ, 2014,349:g4596.
[2]Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China [J]. J Heaptol, 2009,50(1):204-210.
[3]Ma FCh, Zhang QY, Wang Sh, et al. Animal model of nonalcoholic fatty liver disease: research advances [J]. Journal of International Phammaceutical Research, 2017, 44(5):409-414. (in Chinese)
马富超, 张泉洋, 王帅, 等. 非酒精性脂肪肝病动物模型研究进展[J]. 国际药学研究杂志, 2017, 44(5): 409-414.
[4]Li Q, Fu JH. Animal model of nonalcoholic fatty liver disease: research advances [J]. Practical Clinical Journal of Integrate Traditional Chinese and Western Medicine, 2013, 13(3):92-94. (in Chinese)
李强, 傅继华. 非酒精性脂肪肝动物模型研究进展[J]. 实用中西医结合临床, 2013,13(3):92-94.
[5]Zhang HB, Wang Y. Research progress of non-alcoholic fatty liver disease [J]. Hainan Medical Journal, 2017, 28(10):1651-1653. (in Chinese)
张海博, 王宇. 非酒精性脂肪肝的现代研究进展[J]. 海南医学, 2017, 28(10):1651-1653.
[6]Zhang L, Niu ShM, Ma HJ. The Progress of bile acids and metabolic syndrome [J]. Medical Recapitulate, 2016, 22(5): 964-967. (in Chinese)
张柳, 牛尚梅, 马慧娟. 胆汁酸与代谢综合征的研究进展[J]. 医学综述, 2016, 22(5):964-967.
[7]Bonapace S, Perseghin G, Molon G, et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes [J]. Diabetes Care, 2012,35(2):389-395.
[8]Bechmann LP, Kocabayoglu P, Sowa JP, et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis [J]. Hepatology, 2013, 57(4):1394-406.
[9]Liu ST, Liao HY. Clinical research progress of obeticcholic acid [J]. Beijing Medical Journal, 2015, 37(12): 1174-1176. (in Chinse)
刘松涛, 廖慧钰. 奥贝胆酸的临床研究进展[J]. 北京医学, 2015, 37(12): 1174-1176.
[10]Bjursell M, Wedin M, Admyre T, et al. Ageing FXR deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH [J]. PLoS One, 2013, 8(5):e64721.
[11]Ma Y, Huang Y, Yan L, et al. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance [J]. Pharm Res, 2013, 30(5):1447-1457.
[12]Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development [J]. Nat Rev Gastroenterol Hepatol, 2014, 11(1):55-67.
[13]Chen ShQ, Zhang J, Fang QCh. Recent progress of the role of bile acids in regulating glucose, lipid and energy metabolism [J]. Medical Recapitulate, 2016, 22(5):947-950. (in Chinese)
陈淑芹, 张菁, 方启晨. 胆汁酸对糖脂及能量代谢调节作用的研究进展[J]. 医学综述, 2016, 22(5):947-950.
[14]Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial [J]. Lancet, 2015, 385(9972):956-965.
|